Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer

Abstract

The treatment of pancreatic cancer remains a significant clinical challenge due to the limited number of patients eligible for curative (R0) surgery, failures in the clinical development of targeted and immune therapies, and the pervasive acquisition of chemotherapeutic resistance. Refractory pancreatic cancer is typified by high invasiveness and resistance to therapy, with both attributes related to tumor cell stemness. These malignant characteristics mutually enhance each other, leading to rapid cancer progression. Over the past two decades, numerous studies have produced evidence of the pivotal role of glycogen synthase kinase (GSK)3β in the progression of over 25 different cancer types, including pancreatic cancer. In this review, we synthesize the current knowledge on the pathological roles of aberrant GSK3β in supporting tumor cell proliferation and invasion, as well as its contribution to gemcitabine resistance in pancreatic cancer. Importantly, we discuss the central role of GSK3β as a molecular hub that mechanistically connects chemoresistance, tumor cell invasion, and stemness in pancreatic cancer. We also discuss the involvement of GSK3β in the formation of desmoplastic tumor stroma and in promoting anti-cancer immune evasion, both of which constitute major obstacles to successful cancer treatment. Overall, GSK3β has characteristics of a promising therapeutic target to overcome chemoresistance in pancreatic cancer.

Keywords

Pancreatic cancer / chemoresistance / tumor invasion / cancer stemness / glycogen synthase kinase 3β

References

[1] Kleeff J,Apte M.Pancreatic cancer.Nat Rev Dis Primers2016;2:16022

[2] Mizrahi JD,Valle JW.Pancreatic cancer.Lancet2020;395:2008-20

[3] Suker M,Sadot E.FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.Lancet Oncol2016;17:801-10 PMCID:PMC5527756

[4] Goldstein D,Hammel P.nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.J Natl Cancer Inst2015;107:dju413

[5] Wang-Gillam A, Li CP, Bodoky G, et al; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016;387:545-57.

[6] Tempero MA,Chiorean EG.NCCN guidelines insights: pancreatic adenocarcinoma, version 1.2019.J Natl Compr Canc Netw2019;17:202-10

[7] Springfeld C,Büchler MW.Chemotherapy for pancreatic cancer.Presse Med2019;48:e159-74

[8] Christenson ES,Azad NS.Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.Lancet Oncol2020;21:e135-45 PMCID:PMC8011058

[9] Bergman AM,Peters GJ.Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).Drug Resist Updat2002;5:19-33

[10] Binenbaum Y,Gil Z.Gemcitabine resistance in pancreatic ductal adenocarcinoma.Drug Resist Updat2015;23:55-68

[11] Zeng S,Lan B,Pilarsky C.Chemoresistance in pancreatic cancer.Int J Mol Sci2019;20:4504 PMCID:PMC6770382

[12] Sun J,Scarlett CJ.Small molecule inhibitors in pancreatic cancer.RSC Med Chem2020;11:164-83 PMCID:PMC7433757

[13] Carbone D,Panzeca G.1,3,4-Oxadiazole and 1,3,4-thiadiazole nortopsentin derivatives against pancreatic ductal adenocarcinoma: synthesis, cytotoxic activity, and inhibition of CDK1.Mar Drugs2023;21:412 PMCID:PMC10381170

[14] Pishvaian MJ,Brody JR.Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.Lancet Oncol2020;21:508-18 PMCID:PMC7453743

[15] Al-Share B,Diab M.Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy.Cancer Metastasis Rev2021;40:355-71

[16] O’Kane GM.Moving the needle on precision medicine in pancreatic cancer.J Clin Oncol2022;40:2693-705

[17] Jiang H,Knolhoff BL.Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.Nat Med2016;22:851-60 PMCID:PMC4935930

[18] Balachandran VP,Dougan SK.Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities.Gastroenterology2019;156:2056-72 PMCID:PMC6486864

[19] Ullman NA,Dunne RF.Immunologic strategies in pancreatic cancer: making cold tumors hot.J Clin Oncol2022;40:2789-805 PMCID:PMC9390820

[20] Hosein AN,Aguirre AJ.Translational advances in pancreatic ductal adenocarcinoma therapy.Nat Cancer2022;3:272-86

[21] Yang G,Cao Z.Integrative genomic analysis of gemcitabine resistance in pancreatic cancer by patient-derived xenograft models.Clin Cancer Res2021;27:3383-96

[22] de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.Eur J Pharmacol2014;741:8-16

[23] Jia Y.Promising molecular mechanisms responsible for gemcitabine resistance in cancer.Genes Dis2015;2:299-306 PMCID:PMC6150077

[24] Rajabpour A,Teimoori-Toolabi L.Molecular alterations contributing to pancreatic cancer chemoresistance.Pancreatology2017;17:310-20

[25] Adamska A,Emmanouilidi A.Molecular and cellular mechanisms of chemoresistance in pancreatic cancer.Adv Biol Regul2018;68:77-87

[26] Rauchwerger DR,Hedley DW.Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity.Cancer Res2000;60:6075-9

[27] Nakano Y,Koizumi K.Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.Br J Cancer2007;96:457-63 PMCID:PMC2360025

[28] Hagmann W,Löhr JM.Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.Neoplasia2010;12:740-7 PMCID:PMC2933694

[29] Hagmann W,Schnölzer M,Jesnowski R.Membrane drug transporters and chemoresistance in human pancreatic carcinoma.Cancers2010;3:106-25 PMCID:PMC3756352

[30] Saiki Y,Fujimura H.DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.Biochem Biophys Res Commun2012;421:98-104

[31] Dash S,Komuro A.MYC/glutamine dependency is a therapeutic vulnerability in pancreatic cancer with deoxycytidine kinase inactivation-induced gemcitabine resistance.Mol Cancer Res2023;21:444-57

[32] Costantino CL,Kuwano Y.The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.Cancer Res2009;69:4567-72 PMCID:PMC2744447

[33] Nakahira S,Tsujie M.Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.Int J Cancer2007;120:1355-63

[34] Wang C,Fu M,Huang H.Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression.Oncol Rep2015;33:383-90

[35] Minami K,Yamamoto M.Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.J Pharmacol Sci2015;127:319-25

[36] Ng SSW,Chow S.Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.Cancer Res2000;60:5451-5

[37] Akada M,Lattimore S.Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer.Clin Cancer Res2005;11:3094-101

[38] Duxbury MS,Benoit E,Ashley SW.RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance.Clin Cancer Res2005;11:3433-8 PMCID:PMC2734187

[39] Bafna S,Momi N.Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.Br J Cancer2009;101:1155-61 PMCID:PMC2768097

[40] Duxbury MS,Benoit E,Ashley SW.A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells.Cancer Res2004;64:3987-93

[41] Giroux V,Barthet M.p8 is a new target of gemcitabine in pancreatic cancer cells.Clin Cancer Res2006;12:235-41

[42] Bhardwaj V,Lai JCK. Failure of pancreatic cancer chemotherapy: consequences of drug resistance mechanisms. In: Srivastava SK, editor. Pancreatic cancer - molecular mechanism and targets. InTech; 2012. Available from: https://www.intechopen.com/chapters/33494. [Last accessed on 29 Jan 2024]

[43] Wey JS,Fan F.Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells.Br J Cancer2005;93:233-41 PMCID:PMC2361553

[44] Duxbury MS,Zinner MJ,Whang EE.Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.Clin Cancer Res2004;10:2307-18

[45] Arlt A,Müerköster S.Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.Oncogene2003;22:3243-51

[46] Kunnumakkara AB,Krishnan S,Gelovani J.Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products.Cancer Res2007;67:3853-61

[47] Pan X,Yamamoto T.Nuclear factor-κB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells.Clin Cancer Res2008;14:8143-51 PMCID:PMC4403242

[48] Singh S,Bhardwaj A,Singh AP.CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.Br J Cancer2010;103:1671-9 PMCID:PMC2994230

[49] Wang Z,Kong D.Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.Cancer Res2009;69:2400-7 PMCID:PMC2657919

[50] Yao J.Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.Med Oncol2010;27:1017-22

[51] Yao J,Wie JS.Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.Swiss Med Wkly2011;141:w13208

[52] Meidhof S,Lehmann W.ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.EMBO Mol Med2015;7:831-47 PMCID:PMC4459821

[53] Shah AN,Zhang J,Parikh NU.Development and characterization of gemcitabine-resistant pancreatic tumor cells.Ann Surg Oncol2007;14:3629-37

[54] Provenzano PP.Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer.Br J Cancer2013;108:1-8 PMCID:PMC3553539

[55] Hamada S,Shimosegawa T.Inflammation and pancreatic cancer: disease promoter and new therapeutic target.J Gastroenterol2014;49:605-17

[56] Bijlsma MF.The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal.Cancer Metastasis Rev2015;34:97-114

[57] Neesse A,Tuveson DA.Stromal biology and therapy in pancreatic cancer: a changing paradigm.Gut2015;64:1476-84

[58] Rath N.Regulation of pancreatic cancer aggressiveness by stromal stiffening.Nat Med2016;22:462-3

[59] DuFort CC,Hingorani SR.Mounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma.Gastroenterology2016;150:1545-57.e2 PMCID:PMC4957812

[60] Whittle MC.Fibroblasts in pancreatic ductal adenocarcinoma: biological mechanisms and therapeutic targets.Gastroenterology2019;156:2085-96 PMCID:PMC6486863

[61] Herting CJ,Lesinski GB.The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions.Cancer Metastasis Rev2021;40:675-89

[62] Hingorani SR.Epithelial and stromal co-evolution and complicity in pancreatic cancer.Nat Rev Cancer2023;23:57-77 PMCID:PMC10470605

[63] Geller LT,Danino T.Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.Science2017;357:1156-60 PMCID:PMC5727343

[64] Saiki Y,Horii A.Attempts to remodel the pathways of gemcitabine metabolism: recent approaches to overcoming tumours with acquired chemoresistance.Cancer Drug Resist2020;3:819-31 PMCID:PMC8992552

[65] Santofimia-Castaño P.Combating pancreatic cancer chemoresistance by triggering multiple cell death pathways.Pancreatology2021;21:522-9

[66] Garber K.Stromal depletion goes on trial in pancreatic cancer.J Natl Cancer Inst2010;102:448-50

[67] Erkan M,Michalski CW.The role of stroma in pancreatic cancer: diagnostic and therapeutic implications.Nat Rev Gastroenterol Hepatol2012;9:454-67

[68] Provenzano PP,Chang AE,Von Hoff DD.Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.Cancer Cell2012;21:418-29 PMCID:PMC3371414

[69] Vennin C,Morton JP,Pajic M.Reshaping the tumor stroma for treatment of pancreatic cancer.Gastroenterology2018;154:820-38

[70] Neesse A,Öhlund D.Stromal biology and therapy in pancreatic cancer: ready for clinical translation?.Gut2019;68:159-71

[71] Huang H.The next wave of stroma-targeting therapy in pancreatic cancer.Cancer Res2019;79:328-30

[72] Hosein AN,Maitra A.Pancreatic cancer stroma: an update on therapeutic targeting strategies.Nat Rev Gastroenterol Hepatol2020;17:487-505 PMCID:PMC8284850

[73] Carpenter ES,Pasca di Magliano M.Targeting the microenvironment to overcome gemcitabine resistance in pancreatic cancer.Cancer Res2020;80:3070-1

[74] Ho WJ,Zheng L.The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities.Nat Rev Clin Oncol2020;17:527-40 PMCID:PMC7442729

[75] Holohan C,Longley DB.Cancer drug resistance: an evolving paradigm.Nat Rev Cancer2013;13:714-26

[76] Vasan N,Hyman DM.A view on drug resistance in cancer.Nature2019;575:299-309 PMCID:PMC8008476

[77] Tyner JW,Kumaraswamy A.Understanding drug sensitivity and tackling resistance in cancer.Cancer Res2022;82:1448-60 PMCID:PMC9018544

[78] Nguyen LV,Dirks P.Cancer stem cells: an evolving concept.Nat Rev Cancer2012;12:133-43

[79] Batlle E.Cancer stem cells revisited.Nat Med2017;23:1124-34

[80] Dean M,Bates S.Tumour stem cells and drug resistance.Nat Rev Cancer2005;5:275-84

[81] Maugeri-Saccà M,De Maria R.Cancer stem cells and chemosensitivity.Clin Cancer Res2011;17:4942-7

[82] Steinbichler TB,Skvortsov S,Riechelmann H.Therapy resistance mediated by cancer stem cells.Semin Cancer Biol2018;53:156-67

[83] Lytle NK,Reya T.Stem cell fate in cancer growth, progression and therapy resistance.Nat Rev Cancer2018;18:669-80 PMCID:PMC8388042

[84] Borah A,Rochani A,Kumar DS.Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy.Oncogenesis2015;4:e177 PMCID:PMC4670961

[85] Kuhlmann JD,Kurth I,Dubrovska A.Targeting cancer stem cells: promises and challenges.Anticancer Agents Med Chem2016;16:38-58

[86] Clarke MF.Clinical and therapeutic implications of cancer stem cells.N Engl J Med2019;380:2237-45

[87] Raj D,Heeschen C.Concise review: stem cells in pancreatic cancer: from concept to translation.Stem Cells2015;33:2893-902

[88] Sancho P,Usachov V,Sainz B Jr.The ever-changing landscape of pancreatic cancer stem cells.Pancreatology2016;16:489-96

[89] Hermann PC.Pancreatic cancer stem cells: a state or an entity?.Semin Cancer Biol2018;53:223-31

[90] Patil K,Akhtar S,Uddin S.The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance.Cancer Metastasis Rev2021;40:691-720 PMCID:PMC8556195

[91] Pisco AO.Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'What does not kill me strengthens me'.Br J Cancer2015;112:1725-32 PMCID:PMC4647245

[92] Quint K,Di Fazio P.Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition.Int J Oncol2012;41:2093-102

[93] Zhang Y,Wang H.Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer.Oncol Rep2012;27:1599-605

[94] Zhang Z,Zhao H.Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.Cancer Lett2016;382:53-63

[95] Kuo YC,Hsu CP,Hwang TL.Identification and clinical significance of pancreatic cancer stem cells and their chemotherapeutic drug resistance.Int J Mol Sci2023;24:7331 PMCID:PMC10138402

[96] Welch DR.Defining the hallmarks of metastasis.Cancer Res2019;79:3011-27 PMCID:PMC6571042

[97] Brabletz T,Nieto MA.EMT in cancer.Nat Rev Cancer2018;18:128-34

[98] LeBleu VS.The continuing search for causality between epithelial-to-mesenchymal transition and the metastatic fitness of carcinoma cells.Cancer Res2022;82:1467-9

[99] Beuran M,Paun S.The epithelial to mesenchymal transition in pancreatic cancer: a systematic review.Pancreatology2015;15:217-25

[100] Yang AD,Camp ER.Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.Clin Cancer Res2006;12:4147-53

[101] Dallas NA,Fan F.Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.Cancer Res2009;69:1951-7 PMCID:PMC3198868

[102] Kajiyama H,Terauchi M.Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.Int J Oncol2007;31:277-83

[103] Hiscox S,Barrow D,Wakeling A.Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).Clin Exp Metastasis2004;21:201-12

[104] Hiscox S,Obermeier K.Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation.Int J Cancer2006;118:290-301

[105] Li QQ,Wang WJ.Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells.Clin Cancer Res2009;15:2657-65

[106] Fischer KR,Lee S.Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.Nature2015;527:472-6 PMCID:PMC4662610

[107] Fatherree JP,McGinn RA,Oudin MJ.Chemotherapy-induced collagen IV drives cancer cell motility through activation of src and focal adhesion kinase.Cancer Res2022;82:2031-44 PMCID:PMC9381104

[108] Debaugnies M,Blondeau J.RHOJ controls EMT-associated resistance to chemotherapy.Nature2023;616:168-75 PMCID:PMC10076223

[109] Alexander S.Cancer invasion and resistance: interconnected processes of disease progression and therapy failure.Trends Mol Med2012;18:13-26

[110] van Staalduinen J, Baker D, ten Dijke P, van Dam H. Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?.Oncogene2018;37:6195-211

[111] Garg M.Emerging roles of epithelial-mesenchymal plasticity in invasion-metastasis cascade and therapy resistance.Cancer Metastasis Rev2022;41:131-45

[112] Weiss F,Friedl P.Towards targeting of shared mechanisms of cancer metastasis and therapy resistance.Nat Rev Cancer2022;22:157-73 PMCID:PMC10399972

[113] Ebos JML.Prodding the beast: assessing the impact of treatment-induced metastasis.Cancer Res2015;75:3427-35

[114] Karagiannis GS,Oktay MH.Chemotherapy-induced metastasis: molecular mechanisms, clinical manifestations, therapeutic interventions.Cancer Res2019;79:4567-76 PMCID:PMC6744993

[115] Arumugam T,Fournier KF.Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.Cancer Res2009;69:5820-8 PMCID:PMC4378690

[116] Zheng X,Kim J.Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.Nature2015;527:525-30 PMCID:PMC4849281

[117] Polyak K.Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.Nat Rev Cancer2009;9:265-73

[118] Sato R,Saya H.Concise review: stem cells and epithelial-mesenchymal transition in cancer: biological implications and therapeutic targets.Stem Cells2016;34:1997-2007

[119] Zheng X,Feng L,Feng L.Communication between epithelial-mesenchymal plasticity and cancer stem cells: new insights into cancer progression.Front Oncol2021;11:617597 PMCID:PMC8097085

[120] Lambert AW.Linking EMT programmes to normal and neoplastic epithelial stem cells.Nat Rev Cancer2021;21:325-38

[121] Ishiwata T.Cancer stem cells and epithelial-mesenchymal transition: novel therapeutic targets for cancer.Pathol Int2016;66:601-8

[122] Singh A.EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.Oncogene2010;29:4741-51 PMCID:PMC3176718

[123] Shibue T.EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.Nat Rev Clin Oncol2017;14:611-29 PMCID:PMC5720366

[124] Yoneyama H,Takeuchi O.Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones.Anticancer Drugs2015;26:90-100

[125] Machesky LM.Lamellipodia and filopodia in metastasis and invasion.FEBS Lett2008;582:2102-11

[126] Paz H,Yang J.Invading one step at a time: the role of invadopodia in tumor metastasis.Oncogene2014;33:4193-202 PMCID:PMC3969876

[127] Cormier KW.Recent advances in understanding the cellular roles of GSK-3.F1000Res2017;6:167 PMCID:PMC5321126

[128] Patel P.Chapter eight - Glycogen synthase kinase 3: a kinase for all pathways?.Curr Top Dev Biol2017;123:277-302

[129] McCubrey JA.GSK-3 signaling in health.Adv Biol Regul2017;65:1-4

[130] Beurel E,Jope RS.Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.Pharmacol Ther2015;148:114-31 PMCID:PMC4340754

[131] Hoffmeister L,Brand K.GSK3: a kinase balancing promotion and resolution of inflammation.Cells2020;9:820 PMCID:PMC7226814

[132] Pandey MK.Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging.Theranostics2016;6:571-93 PMCID:PMC4775866

[133] Khan I,Alam MS.Natural and synthetic bioactive inhibitors of glycogen synthase kinase.Eur J Med Chem2017;125:464-77

[134] Palomo V.Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat2017;27:657-66

[135] Saraswati AP,Krishna NH,Kamal A.Glycogen synthase kinase-3 and its inhibitors: potential target for various therapeutic conditions.Eur J Med Chem2018;144:843-58

[136] Wei J,Zhang J,Wang G.Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: strategies to improve selectivity.Eur J Med Chem2022;236:114301

[137] Luo J.Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy.Cancer Lett2009;273:194-200 PMCID:PMC4978950

[138] McCubrey JA,Abrams SL.Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy.Adv Biol Regul2014;54:176-96

[139] Tejeda-Muñoz N.Glycogen synthase kinase 3 in Wnt signaling pathway and cancer.IUBMB Life2015;67:914-22

[140] Miyashita K,Shakoori A.An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3β.Anticancer Agents Med Chem2009;9:1114-22

[141] McCubrey JA,Bertrand FE.GSK-3 as potential target for therapeutic intervention in cancer.Oncotarget2014;5:2881-911 PMCID:PMC4102778

[142] Domoto T,Furuta T.Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapy.Cancer Sci2016;107:1363-72 PMCID:PMC5084660

[143] Walz A,Chandra S.Molecular pathways: revisiting glycogen synthase kinase-3β as a target for the treatment of cancer.Clin Cancer Res2017;23:1891-7 PMCID:PMC5392367

[144] Nagini S,Mishra R.Glycogen synthase kinases: moonlighting proteins with theranostic potential in cancer.Semin Cancer Biol2019;56:25-36

[145] Duda P,Abrams SL.Targeting GSK3 and associated signaling pathways involved in cancer.Cells2020;9:1110 PMCID:PMC7290852

[146] Domoto T,Bolidong D.Glycogen synthase kinase 3β in cancer biology and treatment.Cells2020;9:1388 PMCID:PMC7349761

[147] Garcea G,Neal CP.Glycogen synthase kinase-3 beta; a new target in pancreatic cancer?.Curr Cancer Drug Targets2007;7:209-15

[148] Shimasaki T,Motoo Y.Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer.J Carcinog2012;11:15 PMCID:PMC3516047

[149] Zhang Q,Ben-Josef E.Glycogen synthase kinase 3β in pancreatic cancer and its implications in chemotherapy and radiation therapy.J Carcinog Mutagen2013;4:147 PMCID:PMC4059685

[150] Pecoraro C,Balboni B.GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer.Drug Resist Updat2021;58:100779

[151] Park R,Cavalcante L.GSK-3β in pancreatic cancer: spotlight on 9-ING-41, its therapeutic potential and immune modulatory properties.Biology2021;10:610 PMCID:PMC8301062

[152] Elmadbouh OHM,Edderkaoui M.Glycogen synthase kinase 3β: a true foe in pancreatic cancer.Int J Mol Sci2022;23:14133 PMCID:PMC9696080

[153] Osolodkin DI,Zefirov NS.Glycogen synthase kinase 3 as an anticancer drug target: novel experimental findings and trends in the design of inhibitors.Curr Pharm Des2013;19:665-79

[154] Sahin I,De Souza A.Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses.Cancer Biol Ther2019;20:1047-56 PMCID:PMC6606036

[155] Augello G,Cusimano A.The role of GSK-3 in cancer immunotherapy: GSK-3 inhibitors as a new frontier in cancer treatment.Cells2020;9:1427 PMCID:PMC7348946

[156] Ougolkov AV,Savoy DN,Billadeau DD.Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells.Cancer Res2005;65:2076-81

[157] Ougolkov AV,Bilim VN,Chari ST.Aberrant nuclear accumulation of glycogen synthase kinase-3β in human pancreatic cancer: association with kinase activity and tumor dedifferentiation.Clin Cancer Res2006;12:5074-81 PMCID:PMC2692690

[158] Mai W,Shakoori A.Detection of active fraction of glycogen synthase kinase 3β in cancer cells by nonradioisotopic in vitro kinase assay.Oncology2007;71:297-305

[159] Wilson W III.Maintenance of constitutive IκB kinase activity by glycogen synthase kinase-3α/β in pancreatic cancer.Cancer Res2008;68:8156-63 PMCID:PMC2647811

[160] Mai W,Shakoori A.Deregulated GSK3 sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase.Clin Cancer Res2009;15:6810-9

[161] Mamaghani S,Hedley DW.Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy.BMC Cancer2009;9:132 PMCID:PMC2685435

[162] Gaisina IN,Ougolkov AV.From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3β inhibitors that suppress proliferation and survival of pancreatic cancer cells.J Med Chem2009;52:1853-63 PMCID:PMC2665923

[163] Guzmán EA,Linley PA,Wright AE.A novel activity from an old compound: Manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis.Invest New Drugs2011;29:777-85 PMCID:PMC3085053

[164] Zhang JS,Harrison A.Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer.Oncogene2011;30:3705-15 PMCID:PMC3162070

[165] Shimasaki T,Nakamura Y.Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.J Gastroenterol2012;47:321-33

[166] Marchand B,Cagnol S.Inhibition of glycogen synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through JNK-dependent mechanisms.Carcinogenesis2012;33:529-37

[167] Zhou W,Gou SM.ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer.Cancer Lett2012;316:178-86

[168] Mamaghani S,Cao PM.Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis.PLoS One2012;7:e41102 PMCID:PMC3400624

[169] Kitano A,Chikano Y.Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy.PLoS One2013;8:e55289 PMCID:PMC3568118

[170] Zhang JS,Koenig A.Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells.Cell Death Dis2014;5:e1142 PMCID:PMC4067531

[171] Ying X,Ma S.GSK3β mediates pancreatic cancer cell invasion in vitro via the CXCR4/MMP-2 pathway.Cancer Cell Int2015;15:70 PMCID:PMC4513390

[172] Kunnimalaiyaan S,Kunnimalaiyaan M.Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression.HPB2015;17:770-6 PMCID:PMC4557650

[173] Ma S,Pan F.CXCR4 promotes GSK3β expression in pancreatic cancer cells via the Akt pathway.Int J Clin Oncol2015;20:525-30

[174] Baumgart S,Zhang JS.GSK-3β governs inflammation-induced NFATc2 signaling hubs to promote pancreatic cancer progression.Mol Cancer Ther2016;15:491-502 PMCID:PMC6071313

[175] Liu B,Pilarsky C.The effect of GPRC5a on the proliferation, migration ability, chemotherapy resistance, and phosphorylation of GSK-3β in pancreatic cancer.Int J Mol Sci2018;19:1870 PMCID:PMC6073545

[176] Edderkaoui M,Soufi B.An inhibitor of GSK3B and HDACs kills pancreatic cancer cells and slows pancreatic tumor growth and metastasis in mice.Gastroenterology2018;155:1985-98.e5 PMCID:PMC6328046

[177] Kazi A,Yang H.GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors.Nat Commun2018;9:5154 PMCID:PMC6279809

[178] Ding L,Kiers S.Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to chemotherapy by abrogating the TopBP1/ATR-mediated DNA damage response.Clin Cancer Res2019;25:6452-62 PMCID:PMC6825568

[179] Uehara M,Takenaka S.Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.Cancer Sci2020;111:4405-16 PMCID:PMC7734171

[180] Carbone D,Cascioferro S.1,2,4-Oxadiazole topsentin analogs with antiproliferative activity against pancreatic cancer cells, targeting GSK3β kinase.ChemMedChem2021;16:537-54

[181] Abrams SL,Meher AK.GSK-3β can regulate the sensitivity of MIA-PaCa-2 pancreatic and MCF-7 breast cancer cells to chemotherapeutic drugs, targeted therapeutics and nutraceuticals.Cells2021;10:816 PMCID:PMC8067414

[182] Palanivel C,Seshacharyulu P.The GSK3 kinase and LZTR1 protein regulate the stability of Ras family proteins and the proliferation of pancreatic cancer cells.Neoplasia2022;25:28-40 PMCID:PMC8814762

[183] Chikano Y,Furuta T.Glycogen synthase kinase 3β sustains invasion of glioblastoma via the focal adhesion kinase, Rac1, and c-Jun N-terminal kinase-mediated pathway.Mol Cancer Ther2015;14:564-74

[184] Kitabayashi T,Furuta T.Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma.Sci Rep2019;9:10049 PMCID:PMC6624278

[185] Pothula SP,Goldstein D,Wilson JS.Key role of pancreatic stellate cells in pancreatic cancer.Cancer Lett2016;381:194-200

[186] von Ahrens D, Bhagat TD, Nagrath D, Maitra A, Verma A. The role of stromal cancer-associated fibroblasts in pancreatic cancer.J Hematol Oncol2017;10:76 PMCID:PMC5371211

[187] Helms E,Sherman MH.Fibroblast heterogeneity in the pancreatic tumor microenvironment.Cancer Discov2020;10:648-56 PMCID:PMC8261791

[188] Cao F,Sun H,Cui Y.HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer.Oncol Rep2015;33:1883-9

[189] Liu Y,Gao F.Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.Tumour Biol2016;37:15283-91

[190] Zhang H,Guan J.Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells.Oncotarget2015;6:3085-97 PMCID:PMC4413639

[191] Duluc C,Chalabi-Dchar M.Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance.EMBO Mol Med2015;7:735-53 PMCID:PMC4459815

[192] Cao H,Lv X.GSK3 inhibitor-BIO regulates proliferation of immortalized pancreatic mesenchymal stem cells (iPMSCs).PLoS One2012;7:e31502 PMCID:PMC3285662

[193] Bertrand FE.The cross-talk of NOTCH and GSK-3 signaling in colon and other cancers.Biochim Biophys Acta Mol Cell Res2020;1867:118738

[194] Evangelisti C,Paganelli F,Martelli AM.Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer.Biochim Biophys Acta Mol Cell Res2020;1867:118635

[195] Beurel E.Differential regulation of STAT family members by glycogen synthase kinase-3.J Biol Chem2008;283:21934-44 PMCID:PMC2494932

[196] Beurel E.Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain.J Neuroinflammation2009;6:9 PMCID:PMC2660311

[197] Yoon J,Cho SJ.Signal transducers and activators of transcription 3-induced metastatic potential in gastric cancer cells is enhanced by glycogen synthase kinase-3β.APMIS2015;123:373-82

[198] Gao S,Duan X.Inhibition of glycogen synthase kinase 3 beta (GSK3β) suppresses the progression of esophageal squamous cell carcinoma by modifying STAT3 activity.Mol Carcinog2017;56:2301-16 PMCID:PMC5583014

[199] Sahin IH,Hu ZI.Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?.Ann Oncol2017;28:2950-61 PMCID:PMC5834032

[200] Heumann T.Correction to: Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance.Cancer Metastasis Rev2021;40:863-4

[201] Hester R,McAllister F.Immunotherapy in pancreatic adenocarcinoma: beyond “copy/paste”.Clin Cancer Res2021;27:6287-97 PMCID:PMC8639640

[202] Bockorny B,Hidalgo M.Facts and hopes in immunotherapy of pancreatic cancer.Clin Cancer Res2022;28:4606-17

[203] Canel M,Lonergan DW.FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer.Gut2023;73:131-55 PMCID:PMC10715489

[204] Blanco-Gomez A.FAK scaffolds immune escape in pancreatic cancer.Gut2023;73:6-8

[205] Turley SJ,Astarita JL.Immunological hallmarks of stromal cells in the tumour microenvironment.Nat Rev Immunol2015;15:669-82

[206] Barrett RL.Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy.Elife2020;9:e57243 PMCID:PMC7769568

[207] Kennel KB,De Valk AF.Cancer-associated fibroblasts in inflammation and antitumor immunity.Clin Cancer Res2023;29:1009-16 PMCID:PMC10011884